Revisiting use of growth factors in myelodysplastic syndromes

Kam Newman, Lori J Maness-Harris, Ihab El-Hemaidi, Mojtaba Akhtari

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and peripheral blood refractory cytopenias. MDS is recognized to be associated with an increased risk of symptomatic anemia, infectious complications and bleeding diathesis, as well as a risk of progression to acute myeloid leukemia, particularly in patients with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved symptoms in MDS patients in addition to some data that suggest there might be an improvement in survival. G-CSF is an effective therapeutic option in MDS patients, and it should be considered for the management of refractory symptomatic cytopenias. G-CSF and EPO in combination can improve outcomes in appropriate MDS patients such as those with lower-risk MDS and refractory anemia with ring sideroblasts (RARS). This article reviews use of growth factors for lower-risk MDS patients, and examines the data for G-CSF, EPO and thrombopietic growth factors (TPO) that are available or being developed as therapeutic modalities for this challenging disease.

Original languageEnglish (US)
Pages (from-to)1081-1091
Number of pages11
JournalAsian Pacific Journal of Cancer Prevention
Volume13
Issue number4
DOIs
StatePublished - Jan 1 2012

Fingerprint

Myelodysplastic Syndromes
Intercellular Signaling Peptides and Proteins
Granulocyte Colony-Stimulating Factor
Erythropoietin
Refractory Anemia
Disease Susceptibility
Hematopoiesis
Hematologic Neoplasms
Acute Myeloid Leukemia
Anemia
Hemorrhage
Survival
Therapeutics

Keywords

  • Anemia
  • Csf
  • Erythropoiesis stimulating agents
  • G
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Revisiting use of growth factors in myelodysplastic syndromes. / Newman, Kam; Maness-Harris, Lori J; El-Hemaidi, Ihab; Akhtari, Mojtaba.

In: Asian Pacific Journal of Cancer Prevention, Vol. 13, No. 4, 01.01.2012, p. 1081-1091.

Research output: Contribution to journalReview article

Newman, Kam ; Maness-Harris, Lori J ; El-Hemaidi, Ihab ; Akhtari, Mojtaba. / Revisiting use of growth factors in myelodysplastic syndromes. In: Asian Pacific Journal of Cancer Prevention. 2012 ; Vol. 13, No. 4. pp. 1081-1091.
@article{f6ff4519913f46368a062aa061823604,
title = "Revisiting use of growth factors in myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and peripheral blood refractory cytopenias. MDS is recognized to be associated with an increased risk of symptomatic anemia, infectious complications and bleeding diathesis, as well as a risk of progression to acute myeloid leukemia, particularly in patients with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved symptoms in MDS patients in addition to some data that suggest there might be an improvement in survival. G-CSF is an effective therapeutic option in MDS patients, and it should be considered for the management of refractory symptomatic cytopenias. G-CSF and EPO in combination can improve outcomes in appropriate MDS patients such as those with lower-risk MDS and refractory anemia with ring sideroblasts (RARS). This article reviews use of growth factors for lower-risk MDS patients, and examines the data for G-CSF, EPO and thrombopietic growth factors (TPO) that are available or being developed as therapeutic modalities for this challenging disease.",
keywords = "Anemia, Csf, Erythropoiesis stimulating agents, G, Myelodysplastic syndromes",
author = "Kam Newman and Maness-Harris, {Lori J} and Ihab El-Hemaidi and Mojtaba Akhtari",
year = "2012",
month = "1",
day = "1",
doi = "10.7314/APJCP.2012.13.4.1081",
language = "English (US)",
volume = "13",
pages = "1081--1091",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "4",

}

TY - JOUR

T1 - Revisiting use of growth factors in myelodysplastic syndromes

AU - Newman, Kam

AU - Maness-Harris, Lori J

AU - El-Hemaidi, Ihab

AU - Akhtari, Mojtaba

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and peripheral blood refractory cytopenias. MDS is recognized to be associated with an increased risk of symptomatic anemia, infectious complications and bleeding diathesis, as well as a risk of progression to acute myeloid leukemia, particularly in patients with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved symptoms in MDS patients in addition to some data that suggest there might be an improvement in survival. G-CSF is an effective therapeutic option in MDS patients, and it should be considered for the management of refractory symptomatic cytopenias. G-CSF and EPO in combination can improve outcomes in appropriate MDS patients such as those with lower-risk MDS and refractory anemia with ring sideroblasts (RARS). This article reviews use of growth factors for lower-risk MDS patients, and examines the data for G-CSF, EPO and thrombopietic growth factors (TPO) that are available or being developed as therapeutic modalities for this challenging disease.

AB - Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematologic neoplasms characterized by morphologic dysplasia, aberrant hematopoiesis and peripheral blood refractory cytopenias. MDS is recognized to be associated with an increased risk of symptomatic anemia, infectious complications and bleeding diathesis, as well as a risk of progression to acute myeloid leukemia, particularly in patients with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved symptoms in MDS patients in addition to some data that suggest there might be an improvement in survival. G-CSF is an effective therapeutic option in MDS patients, and it should be considered for the management of refractory symptomatic cytopenias. G-CSF and EPO in combination can improve outcomes in appropriate MDS patients such as those with lower-risk MDS and refractory anemia with ring sideroblasts (RARS). This article reviews use of growth factors for lower-risk MDS patients, and examines the data for G-CSF, EPO and thrombopietic growth factors (TPO) that are available or being developed as therapeutic modalities for this challenging disease.

KW - Anemia

KW - Csf

KW - Erythropoiesis stimulating agents

KW - G

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84873032058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873032058&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2012.13.4.1081

DO - 10.7314/APJCP.2012.13.4.1081

M3 - Review article

VL - 13

SP - 1081

EP - 1091

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 4

ER -